Figure 5.

HER2‐mediated signaling pathways in HER2‐positive hepatoma cells. Effect of HER2 inhibitor, Transtuzumab, on the activation and expression of the major signal molecular at 10 min after 10 nM EGF stimulation in HepG2, JM1 and McA+HER2 assessed by Western blotting. β‐tubulin was set as the internal control. The result indicated that HER2 may affect the biological characteristics of hepatoma cells through both TGF‐β/SMAD2/3 and WNT/β‐catenin signal pathways. HER2 degradation through Transtuzumab may function as β‐catenin suppression and SMAD3 and SMAD2/3 complex activation.